CA2410968A1 - Method of treating chronic ulcers - Google Patents
Method of treating chronic ulcers Download PDFInfo
- Publication number
- CA2410968A1 CA2410968A1 CA002410968A CA2410968A CA2410968A1 CA 2410968 A1 CA2410968 A1 CA 2410968A1 CA 002410968 A CA002410968 A CA 002410968A CA 2410968 A CA2410968 A CA 2410968A CA 2410968 A1 CA2410968 A1 CA 2410968A1
- Authority
- CA
- Canada
- Prior art keywords
- matrix
- ulcer
- amino acids
- polar amino
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/18—Materials or treatment for tissue regeneration for hair reconstruction
Abstract
The invention provides a method of treating a chronic ulcer, such as a diabetic ulcer, comprising administering a therapeutic amount of a hydrogen matrix to the ulcer, the matrix composition comprising gelatin and a long chain carbohydrate. The matrix may further include polar amino acids, nitric oxide inhibitors and super oxide inhibitors. Injection is a preferred method of administration. The matrix may be injected into one or more locations within the ulcer, underneath the ulcer and/or around the periphery of the ulcer.
Claims (31)
1. A method of treating an ulcer, comprising administering a therapeutic amount of a hydrogel matrix to the ulcer, the matrix composition comprising gelatin and a long chain carbohydrate.
2. The method of Claim 1, wherein the matrix comprises about 0.01 to about 40 mM gelatin.
3. The method of Claim 1, wherein the gelatin comprises denatured collagen.
4. The method of Claim 1, wherein the long chain carbohydrate comprises dextran.
5. The method of Claim 4, wherein the matrix comprises about 0.01 to about mM dextran.
6. The method of Claim 1, wherein the long chain carbohydrate has a molecular weight of about 20,000 to about 1,000,000 Daltons.
7. The method of Claim 1, wherein the matrix further comprises an effective amount of polar amino acids selected from the group consisting of arginine, lysine, histidine, glutamic acid, and aspartic acid.
8. The method of Claim 7, wherein the effective amount of polar amino acids comprises about 3 to about 150 mM of polar amino acids.
9. The method of Claim 7, wherein the effective amount of polar amino acids comprises about 10 to about 65 mM of polar amino acids.
10. The method of Claim 7, wherein the polar amino acids are selected from the group consisting of arginine, glutamic acid, lysine and mixtures thereof.
11. The method according to claim 10, wherein the matrix comprises:
about 2 to about 60 mM of L-glutamic acid;
about 0.5 to about 30 mM of L-lysine; and about 1 to about 40 mM of arginine.
about 2 to about 60 mM of L-glutamic acid;
about 0.5 to about 30 mM of L-lysine; and about 1 to about 40 mM of arginine.
12. The method of Claim 11, wherein the matrix comprises:
about 5 to about 40 mM of L-glutamic acid;
about 1 to about 15 mM of L-lysine; and about 1 to about 30 mM of arginine.
about 5 to about 40 mM of L-glutamic acid;
about 1 to about 15 mM of L-lysine; and about 1 to about 30 mM of arginine.
13. The method according to claim 10, wherein the effective amount of polar amino acids comprises about 2 to about 60 mM of L-glutamic acid.
14. The method according to claim 10, wherein the effective amount of polar amino acids comprises about 1 to about 40 mM of arginine.
15. The method of Claim 10, wherein the effective amount of polar amino acids comprises about 0.5 to about 30 mM of L-lysine.
16. The method of Claim 1, wherein the matrix further comprises at least one nitric oxide inhibitor.
17. The method of Claim 16, wherein the nitric oxide inhibitor is selected from the group consisting of L-cysteine, L-arginine analogues, cystine, heparin, and mixtures thereof.
18. The method of Claim 16, wherein the nitric oxide inhibitor is present in an amount of about 5 to about 1000 µM.
19. The method of Claim 16, wherein the nitric oxide inhibitor is present in an amount of about 20 to about 200 µM.
20. The method of Claim 1, wherein the matrix further comprises about 5 to about 500 µM of L-cysteine.
21. The method of Claim 20, wherein the matrix comprises about 15 to about 25 µM of L-cysteine.
22. The method of Claim 1, wherein the matrix further comprises about 5 to about 500 µM of an L-arginine analogue.
23. The method of Claim 22, wherein the L-arginine analogue comprises aminoguanidine.
24. The method of Claim 22, wherein the matrix comprises about 15 to about
25 µM of an L-arginine analogue.
25. The method of Claim 1, wherein the matrix further comprises a superoxide inhibitor.
25. The method of Claim 1, wherein the matrix further comprises a superoxide inhibitor.
26. The method of Claim 25, wherein the superoxide inhibitor comprises EDTA or a salt thereof.
27. The method of Claim 25, wherein the superoxide inhibitor is present in an amount of about 1 to about 8 mM.
28. The method of claim 1, wherein the gelatin comprises denatured collagen and the long chain carbohydrate comprises dextran.
29. The method of Claim 1, wherein said administering step comprises injecting the matrix into one or more locations selected from the group consisting of locations within the ulcer, locations around the periphery of the ulcer, locations underneath the ulcer and combinations thereof.
30. The method of Claim 1, wherein the therapeutic amount comprises about 1.0 to about 60 ml.
31. The method of Claim 1, wherein the ulcer is a diabetic foot ulcer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20811600P | 2000-05-31 | 2000-05-31 | |
US60/208,116 | 2000-05-31 | ||
PCT/US2001/017387 WO2001091774A2 (en) | 2000-05-31 | 2001-05-30 | Method of treating chronic ulcers |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2410968A1 true CA2410968A1 (en) | 2001-12-06 |
CA2410968C CA2410968C (en) | 2011-03-29 |
Family
ID=22773242
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2410968A Expired - Fee Related CA2410968C (en) | 2000-05-31 | 2001-05-30 | Method of treating chronic ulcers |
CA2410965A Expired - Fee Related CA2410965C (en) | 2000-05-31 | 2001-05-30 | Method of stimulating hair growth |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2410965A Expired - Fee Related CA2410965C (en) | 2000-05-31 | 2001-05-30 | Method of stimulating hair growth |
Country Status (8)
Country | Link |
---|---|
US (2) | US7700660B2 (en) |
EP (1) | EP1289537B1 (en) |
AT (1) | ATE311192T1 (en) |
AU (3) | AU2001263495B2 (en) |
CA (2) | CA2410968C (en) |
DE (1) | DE60115433T2 (en) |
NZ (1) | NZ523461A (en) |
WO (2) | WO2001091774A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7828749B2 (en) * | 1996-05-17 | 2010-11-09 | Roche Diagnostics Operations, Inc. | Blood and interstitial fluid sampling device |
WO2004082459A2 (en) * | 2003-03-13 | 2004-09-30 | Burgess Cheryl M | Methods of administering a material into a patient for dermal enhancement |
JP2005269232A (en) * | 2004-03-18 | 2005-09-29 | Renesas Technology Corp | Frequency mixer |
US8829051B2 (en) * | 2004-05-24 | 2014-09-09 | Geoffrey C. GURTNER | Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux |
WO2009137074A1 (en) * | 2008-05-06 | 2009-11-12 | Indigene Pharmaceuticals, Inc. | Compositions and methods for treating diabetic ulcers |
US10098857B2 (en) | 2008-10-10 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds |
EP2236617A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Methods of terminal sterilization of biofunctional compositions |
AU2010314994B2 (en) | 2009-11-09 | 2016-10-06 | Spotlight Technology Partners Llc | Fragmented hydrogels |
WO2011057131A1 (en) | 2009-11-09 | 2011-05-12 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
WO2013067195A1 (en) | 2011-11-02 | 2013-05-10 | Halscion, Inc. | Methods and compositions for wound treatment |
WO2013096650A2 (en) | 2011-12-23 | 2013-06-27 | Pioneer Surgical Technology | Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith |
US11931325B2 (en) * | 2015-10-20 | 2024-03-19 | Eaderm Co., Ltd. | Hair-growth promoting composition and usage thereof |
KR102085404B1 (en) * | 2016-08-31 | 2020-03-05 | 주식회사 에스엔비아 | Composition for treatment of partial obesity and microneedle comprising the composition |
EP3558243B1 (en) | 2016-12-21 | 2022-10-05 | Unilever IP Holdings B.V. | Personal care compositions comprising poorly soluble compounds |
EA038885B1 (en) | 2016-12-21 | 2021-11-02 | ЮНИЛЕВЕР АйПи ХОЛДИНГС Б.В. | Topical skin lightening additive and composition with amino acids and nicotinamide compounds |
CA3046037A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids |
JP7082623B2 (en) | 2016-12-21 | 2022-06-08 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | Composition for personal care with cystine |
WO2019055490A1 (en) | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Conditioning irradiated tissue for fat graft retention |
JP2021526127A (en) | 2018-05-23 | 2021-09-30 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Nanoemulsion and its manufacturing method |
CN113679846B (en) * | 2021-08-31 | 2023-05-09 | 佛山市第一人民医院(中山大学附属佛山医院) | Hair regenerating agent and preparation method and application thereof |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4198479A (en) | 1979-03-30 | 1980-04-15 | Merck & Co., Inc. | Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells |
US4520821A (en) | 1982-04-30 | 1985-06-04 | The Regents Of The University Of California | Growing of long-term biological tissue correction structures in vivo |
US4657866A (en) * | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US5852009A (en) | 1984-03-19 | 1998-12-22 | The Rockefeller University | Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon |
US4665192A (en) * | 1984-03-19 | 1987-05-12 | The Rockefeller University | 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole |
US4868121A (en) | 1985-02-07 | 1989-09-19 | Mcdonnell Douglas Corporation | Islet isolation process |
NO166836C (en) * | 1985-03-14 | 1991-09-11 | Univ California | PROCEDURE FOR TREATMENT OF AN ORGAN TRANSPLANT. |
AU589438B2 (en) | 1985-08-26 | 1989-10-12 | Hana Biologics, Inc. | Transplantable artificial tissue and process |
US4902295A (en) | 1985-08-26 | 1990-02-20 | Hana Biologics, Inc. | Transplantable artificial tissue |
GB8604497D0 (en) * | 1986-02-24 | 1986-04-03 | Connaught Lab | Separation of islets of langerhans |
FR2600076A1 (en) * | 1986-06-12 | 1987-12-18 | Fond Ctre Nal Transfusion | CULTURE MEDIUM COMPRISING HUMAN ALBUMIN, PROCESS FOR PREPARING A PRODUCT INJECTABLE THEREFROM, PRODUCT OBTAINED AND USE THEREOF, COMPOSITION OBTAINED |
US5079160A (en) * | 1987-06-08 | 1992-01-07 | Lacy Paul E | Method to isolate clusters of cell subtypes from organs |
US5457093A (en) | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
AU632273B2 (en) | 1988-03-09 | 1992-12-24 | Terumo Kabushiki Kaisha | Medical material permitting cells to enter thereinto and artificial skin |
US4950483A (en) * | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
EP0363125A3 (en) | 1988-10-03 | 1990-08-16 | Hana Biologics Inc. | Proliferated pancreatic endocrine cell product and process |
US4957902A (en) | 1988-12-20 | 1990-09-18 | Board Of Regents, The University Of Texas System | Peptide inhibitors of wound contraction |
US5059588A (en) * | 1989-10-13 | 1991-10-22 | Procyte Corporation, Incorporated | Methods and compositions for healing bone using gly his lys: copper |
WO1991009119A1 (en) | 1989-12-13 | 1991-06-27 | Trancel Corporation | Improved alginate microcapsules, methods of making and using same |
US5645591A (en) * | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
US5336616A (en) | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US5192312A (en) * | 1991-03-05 | 1993-03-09 | Colorado State University Research Foundation | Treated tissue for implantation and methods of treatment and use |
DK0585368T3 (en) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implantable biocompatible immuno-insulating vehicle for delivery of selected therapeutic products |
US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
CA2071137A1 (en) | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
US5591709A (en) | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
WO1994015589A1 (en) | 1992-12-30 | 1994-07-21 | Clover Consolidated, Limited | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials |
US5358969A (en) * | 1991-12-16 | 1994-10-25 | Washington University | Method of inhibiting nitric oxide formation |
US5246971A (en) | 1991-12-16 | 1993-09-21 | Washington University | Method of inhibiting nitric oxide formation |
US5824331A (en) * | 1992-02-24 | 1998-10-20 | Encelle, Inc. | Bioartificial devices and cellular matrices therefor |
US5834005A (en) | 1992-02-24 | 1998-11-10 | Encelle, Inc. | Bioartificial devices and cellular matrices therefor |
CA2109065C (en) | 1992-02-24 | 2004-03-30 | Anton-Lewis Usala | Bioartificial endocrine device |
US5830492A (en) | 1992-02-24 | 1998-11-03 | Encelle, Inc. | Bioartificial devices and cellular matrices therefor |
US6231881B1 (en) * | 1992-02-24 | 2001-05-15 | Anton-Lewis Usala | Medium and matrix for long-term proliferation of cells |
AU3733293A (en) | 1992-02-25 | 1993-09-13 | Alteon Inc. | Method and agents for promoting wound healing |
EP0641196B1 (en) | 1992-05-29 | 2001-08-22 | Vivorx, Incorporated | Microencapsulation of cells |
EP0655910A4 (en) | 1992-07-29 | 1996-02-28 | Univ Washington | Use of pouch for implantation of living cells. |
US5262055A (en) | 1992-10-19 | 1993-11-16 | The University Of Utah | Implantable and refillable biohybrid artificial pancreas |
DE4431598C2 (en) | 1993-03-03 | 1997-03-20 | Michael Sittinger | Process for producing an implant from cell cultures |
DE69434626D1 (en) | 1993-11-17 | 2006-04-20 | Athena Neurosciences Inc | TRANSPARENT LIQUID FOR THE ADMINISTRATION OF CAPTIVATED MEDICAMENTS |
ATE408005T1 (en) | 1994-01-13 | 2008-09-15 | Rogosin Inst | MACRO-ENCAPSULED SECRETORY CELLS |
US5487899A (en) * | 1994-01-31 | 1996-01-30 | Jess Clarke & Sons, Inc. | Wound healing |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
US5840059A (en) * | 1995-06-07 | 1998-11-24 | Cardiogenesis Corporation | Therapeutic and diagnostic agent delivery |
CA2179341A1 (en) | 1996-04-12 | 1997-10-13 | Gregory S. Korbutt | Methods for isolating, enriching and increasing the maturation of cells |
CA2251129A1 (en) * | 1996-05-03 | 1997-11-13 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
US5972332A (en) * | 1997-04-16 | 1999-10-26 | The Regents Of The University Of Michigan | Wound treatment with keratinocytes on a solid support enclosed in a porous material |
EP0986408B1 (en) * | 1997-06-03 | 2005-05-11 | Innogenetics N.V. | New medicaments based on polymers composed of methacrylamide-modified gelatin |
CN1283997A (en) * | 1997-12-22 | 2001-02-14 | 人类基因组科学公司 | Keratinocyte growth factor-2 formulations |
CA2337051C (en) * | 1998-07-10 | 2007-04-17 | Encelle, Inc. | Methods for increasing vascularization and promoting wound healing |
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US6046160A (en) * | 1999-07-22 | 2000-04-04 | Deroyal Industries, Inc. | Composition and method for enhancing wound healing |
US6491953B1 (en) * | 2000-01-07 | 2002-12-10 | Amcol International Corporation | Controlled release compositions and method |
US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
-
2001
- 2001-05-30 EP EP01937796A patent/EP1289537B1/en not_active Expired - Lifetime
- 2001-05-30 CA CA2410968A patent/CA2410968C/en not_active Expired - Fee Related
- 2001-05-30 NZ NZ523461A patent/NZ523461A/en not_active IP Right Cessation
- 2001-05-30 AT AT01937796T patent/ATE311192T1/en not_active IP Right Cessation
- 2001-05-30 AU AU2001263495A patent/AU2001263495B2/en not_active Ceased
- 2001-05-30 US US09/870,414 patent/US7700660B2/en not_active Expired - Fee Related
- 2001-05-30 WO PCT/US2001/017387 patent/WO2001091774A2/en active IP Right Grant
- 2001-05-30 US US09/870,424 patent/US6992062B2/en not_active Expired - Fee Related
- 2001-05-30 AU AU2001265151A patent/AU2001265151A1/en not_active Abandoned
- 2001-05-30 CA CA2410965A patent/CA2410965C/en not_active Expired - Fee Related
- 2001-05-30 WO PCT/US2001/017386 patent/WO2001091773A2/en active Application Filing
- 2001-05-30 DE DE60115433T patent/DE60115433T2/en not_active Expired - Lifetime
- 2001-05-30 AU AU6349501A patent/AU6349501A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DE60115433D1 (en) | 2006-01-05 |
AU2001265151A1 (en) | 2001-12-11 |
US20020077277A1 (en) | 2002-06-20 |
US20020065222A1 (en) | 2002-05-30 |
WO2001091773A3 (en) | 2002-05-02 |
NZ523461A (en) | 2004-11-26 |
WO2001091774A2 (en) | 2001-12-06 |
EP1289537B1 (en) | 2005-11-30 |
CA2410965A1 (en) | 2001-12-06 |
ATE311192T1 (en) | 2005-12-15 |
CA2410968C (en) | 2011-03-29 |
AU6349501A (en) | 2001-12-11 |
EP1289537A2 (en) | 2003-03-12 |
US7700660B2 (en) | 2010-04-20 |
WO2001091774A3 (en) | 2002-05-02 |
DE60115433T2 (en) | 2006-08-03 |
US6992062B2 (en) | 2006-01-31 |
CA2410965C (en) | 2010-09-14 |
AU2001263495B2 (en) | 2005-06-02 |
WO2001091773A2 (en) | 2001-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2410968A1 (en) | Method of treating chronic ulcers | |
ATE326243T1 (en) | METHODS TO IMPROVE VASCULARIZATION AND PROMOTE WOUND HEALING | |
Gorham et al. | Effect of chemical modifications on the susceptibility of collagen to proteolysis. II. Dehydrothermal crosslinking | |
EP1321516A3 (en) | Hydrogel matrix for cellular tissue storage | |
MXPA04004170A (en) | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors. | |
CA2275890A1 (en) | Stable liquid interferon formulations | |
KR900002801A (en) | Pharmaceutical preparations for treating diabetes | |
KR910009246A (en) | Subcutaneous or intramuscular administration containing the polypeptide | |
AU2001263495A1 (en) | Method of treating chronic ulcers | |
AU2002309121A1 (en) | Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field | |
Akopyan et al. | Acid proteinase of hypothalamus: purification, some properties, and action on somatostatin and substance P | |
NO955067L (en) | FVII / TF peptides | |
FI95999C (en) | K2P-prostabilointi | |
PT1296675E (en) | COMPOSITIONS BASED ON AMINOACIDES SUITABLE FOR THE TREATMENT OF INSUFFICIENCIACARDIACA | |
Kamata et al. | Characterization of the complex between α2-macroglobulin and a serine proteinase from Bacillus natto | |
CA2337051A1 (en) | Methods for increasing vascularization and promoting wound healing | |
JP3393652B2 (en) | A novel protease inhibitor derived from gamarin | |
Ohkubo et al. | A novel serine protease complexed with α2-macroglobulin from skeletal muscle of lizard fish (Saurida undosquamis) | |
Glovinsky et al. | Binding and processing of trypsin by cultured bovine corneal endothelial cells | |
UEKI et al. | Inhibition by equine α2-macroglobulin of an N-succinyl-L-trialanine p-nitroanilide-hydrolyzing protease purified from pronase | |
CN1958790A (en) | New thrombin in snake poison categories of hundred-paced pit viper, and styptic activity | |
Willis | Atroxase, a nonhemorrhagic fibrinolytic protease from the venom of Crotalus atrox. | |
植木寛 et al. | Inhibition by equine. ALPHA. 2-macroglobulin of an N-succinyl-L-trialanine p-nitroanilide-hydrolyzing protease purified from pronase. | |
FR2185416A1 (en) | Isotonic injectable ACTH compsns - with low content of polyphloretin phosphate, but with prolonged activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20200831 |